• Male or female,≥18 years old;

• Histologically confirmed diagnosis of B-ALL or B-NHL(meeting one of the following conditions):

‣ (B-NHL)

⁃ Second or greater relapse (CD20 regimens must be included) OR

⁃ Refractory to first-line chemotherapy or relapse within 1 year OR

⁃ Relapse within 1 year of auto-HSCT.

⁃ With measurable or evaluable lesions（Dose expansion cohort） (B-ALL)

‣ a. Relapse within 12 months of complete remission on first treatment OR b. Relapse after second-line treatment OR c. Relapse after auto HST OR d. Failure to achieve CR/CRi at the end of induction therapy OR e. Ph+ ALL intolerance to TKI or refractory or relapse after treatment with at least two and more TKIs.

• ECOG 0\

‣ 2

• Estimated survival time ≥ 12 weeks;

• Main tissues and organs function well.